In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic
anemia in myelodysplastic syndromes, beta - thalassemia, and myelofibrosis.
A donor made a $ 1,009,220 contribution to the MDS - Leukemia Stem Cell Research Center at Columbia University Irving Medical Center to advance clinical and basic
research in myelodysplastic syndrome and leukemia.
Temple University Hospital and Fox Chase Cancer Center are the only two sites in Philadelphia that participated in an international phase I, randomized clinical trial which tested the drug guadecitabine (SGI - 110)
in Myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML).